Goldman Sachs Group Inc Intra Cellular Therapies, Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 376,417 shares of ITCI stock, worth $49.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
376,417
Previous 456,030
17.46%
Holding current value
$49.4 Million
Previous $33.3 Million
5.72%
% of portfolio
0.01%
Previous 0.01%
Shares
20 transactions
Others Institutions Holding ITCI
# of Institutions
419Shares Held
88.8MCall Options Held
284KPut Options Held
105K-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.28 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$830 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$673 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$427 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$422 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.4B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...